Amorphous Solid Dispersion for HCV Drug Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, such as those using peginterferon-alpha and ribavirin, suffer from substantial limitations in efficacy and tolerability, with inadequate viral elimination and significant side effects, necessitating the development of new drugs.
Innovation Solution
The development of solid compositions comprising potent HCV inhibiting compounds, specifically Compound IA, IB, and IC, in an amorphous form combined with pharmaceutically acceptable hydrophilic polymers and surfactants, which enhance drug solubility and bioavailability through solid dispersions or solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new HCV inhibiting compounds are developed to improve efficacy, then viral elimination is enhanced, but drug solubility and bioavailability become limiting factors
Solution Approach 1:
The patent changes the physical state parameter of the drug compound from crystalline to amorphous form. This parameter change increases drug solubility and bioavailability without altering the chemical structure or efficacy of the HCV inhibiting compound, thereby resolving the contradiction between efficacy and solubility
Solution Approach 2:
The patent creates a composite solid dispersion system combining the HCV inhibiting compound with hydrophilic polymers (such as polyvinylpyrrolidone, hydroxypropyl methylcellulose). This composite material approach enhances drug solubility and bioavailability while maintaining the active compound's efficacy against HCV
2Adaptability or versatility
If conventional treatments like peginterferon-alpha and ribavirin are used, then treatment coverage is established, but side effects increase and tolerability decreases
Solution Approach 1:
The patent extracts and focuses on a specific mechanistic target (HCV protease or polymerase) rather than using broad-spectrum antivirals. By developing compounds that specifically inhibit HCV replication enzymes, the treatment achieves effective coverage while reducing off-target side effects associated with conventional therapies
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular structures (Compound IA, IB, IC) that target particular HCV replication mechanisms. This localized molecular approach allows effective viral inhibition while minimizing systemic side effects through selective action
3Reliability
If HCV inhibiting compounds are administered to achieve viral inhibition, then treatment effectiveness is improved, but drug absorption and bioavailability remain insufficient
Solution Approach 1:
The patent changes the physical parameter of the drug from crystalline to amorphous state, which fundamentally improves dissolution rate and bioavailability. This parameter change enables better drug absorption while maintaining the compound's viral inhibition effectiveness
Solution Approach 2:
The patent introduces hydrophilic polymers as intermediary substances that facilitate drug absorption. These polymers act as mediators between the HCV inhibiting compound and the biological system, enhancing bioavailability without interfering with the compound's antiviral mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid compositions significantly improve the bioavailability and absorption of HCV inhibiting compounds, potentially offering more effective treatment options with reduced side effects by maintaining the compounds in a supersaturated state and enhancing their dissolution rates.
Implementation Method 1
wherein said HCV inhibiting compound is in an amorphous form
Implementation Method 2
The solid compositions of the invention comprise (1) a compound selected from Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form, (2) a pharmaceutically acceptable hydrophilic polymer, and optionally (3) a pharmaceutically acceptable surfactant
Implementation Method 3
by maintaining the compounds in a supersaturated state and enhancing their dissolution rates
Data Source
AI summary
The present invention features solid compositions comprising Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.